413 FIBROTEST (FT) VALUE INDEPENDENTLY PREDICTS EARLY (EVR) AND SUSTAINED VIROLOGICAL RESPONSE (SVR) IN NON-RESPONDER PATIENTS RE-TREATED WITH PEGYLATED INTERFERON ALFA-2B (PEG-2B) AND RIBAVIRIN IN EPIC3

Journal article

Peer reviewed

T. Poynard, E.R. Schiff, R. Terg, R. Moreno-Otero, S.L. Flamm, W. Schmidt, T. Berg, F.L. Goncales, J.E. Heathcote, M. Diago, …

Journal of hepatology, Vol.50, pp.S156-S156

2009-04

Metrics

1 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Industry collaboration; Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.125 Hepatitis; 1.125.663 NAFLD
Web Of Science research areas: Gastroenterology & Hepatology
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: 413 FIBROTEST (FT) VALUE INDEPENDENTLY PREDICTS EARLY (EVR) AND SUSTAINED VIROLOGICAL RESPONSE (SVR) IN NON-RESPONDER PATIENTS RE-TREATED WITH PEGYLATED INTERFERON ALFA-2B (PEG-2B) AND RIBAVIRIN IN EPIC3
Creators: T. Poynard
E.R. Schiff
R. Terg
R. Moreno-Otero
S.L. Flamm
W. Schmidt
T. Berg
F.L. Goncales
J.E. Heathcote
M. Diago
T. McGarrity
P. Bedossa
H. Zhou
P. Mukhopadhyay
L.H. Griffel
M. Burroughs
C.A. Brass
J.K. Albrecht
Publication Details: Journal of hepatology, Vol.50, pp.S156-S156
Academic Unit: Leadership Department; Miller School of Medicine; UMMG Dept of Medicine - Hepatology
Language: English
Resource Type: Journal article
Record Identifier: 991031714052202976